END DIABETES STIGMA.

What To Know About The New Tandem Mobi: A 7-Day Tubeless AID System

Written by: Christine Fallabel

3 minute read

November 17, 2026

Medically reviewed by: Beyond Type 1 Clinical Team

On Friday, the Food and Drug Administration (FDA) cleared the tubeless Tandem Mobi. This makes it the world’s first tubeless automated insulin delivery (AID) system that can be worn for up to seven days. The Tandem Mobi is also the world’s smallest insulin pump that can be worn tubed or tubeless.

Joining Insulet’s Omnipod 5 system, this clearance gives people with diabetes, many of whom have wanted more tubeless choices for years, another option and more flexibility in how they manage their diabetes.

How does the new tubeless system work?

A new Tandem Mobi tubeless cartridge and infusion set will convert current users’ Mobi insulin pump system into a tubeless device, while keeping the Control-IQ+ technology for automated insulin delivery. 

If you prefer the tubed version, that’s still an option. The Tandem Mobi is now cleared for both tubeless and tubed use, letting you choose whichever wear option best fits your needs.

“The Tandem Mobi insulin pump was originally designed to make different wear options possible, which now includes a tubeless option with up to seven days of wear,” said John Sheridan, president and chief executive officer. “This clearance of the Tandem Mobi tubeless cartridge and infusion set creates even more possibilities for people living with diabetes, expanding the number of ways to experience the proven benefits of our Control-IQ+ AID technology.” 

Here’s what the Tandem Mobi system includes:

  • A tubeless infusion set cleared for up to seven days of wear (the insulin cartridge itself is cleared for three days of use)
  • A 200-unit insulin cartridge (equal to Omnipod 5)
  • Inductive (wireless) charging
  • Water resistance (rated IP28)
  • Remote software updates
  • Wireless uploads of pump and therapy data to Tandem Source, Tandem’s cloud-based platform
  • Control from a compatible smartphone through the Tandem Mobi mobile app
  • The option to temporarily disconnect for activities like saunas, hot tubs or exercise

A longer-lasting infusion set means fewer pokes, site changes and disruptions in your daily life. If you’ve felt limited by a tubed pump, more choices mean more freedom.

How does Control-IQ+ work?

Their Control-IQ technology uses compatible continuous glucose monitor (CGM) sensor readings to predict glucose levels 30 minutes in the future. It then adjusts basal insulin delivery every five minutes to combat both high and low blood glucose levels. The system also delivers automatic correction boluses of insulin for up to once an hour for glucose readings above 180mg/dL.

The Tandem Control-IQ+ AID system was first approved by the FDA in 2019, and its successor, the Tandem Mobi, was FDA-approved in 2023. Despite its popular algorithm and features, the diabetes community has requested more flexibility in wear, including a tubeless option, for years.

Control-IQ+ is cleared for people with type 1 diabetes (T1D) ages 2 and older and adults with type 2 diabetes (T2D) ages 18 and older.

When will the Tubeless Tandem Mobi AID System be available?

Full commercial launch of the tubeless Tandem Mobi is slated for early 2027 in the U.S. Existing Tandem Mobi users will not need a new insulin pump to upgrade since the current system is compatible with the new tubeless infusion sets and cartridges.

Tandem will contact eligible users with more information on how to upgrade to the new sets once they become available. Users will not need a new prescription from their healthcare team to make the switch. 

New tech is one part of living well with diabetes. Stay up to date on the latest with our Diabetes Technology Guide.

Author

Christine Fallabel

Christine Fallabel has been living with type 1 diabetes since 2000. She's a health and science writer and has been featured in Diabetes Daily Grind, Insulin Nation, Diabetics Doing Things, and is a regular contributor to Diabetes Strong, T1D Exchange and Healthline. She earned her Master of Public Health from Temple University and received her Bachelor of Arts from The University of Delaware. In her spare time, she enjoys hiking with her husband in the mountains of Colorado, tinkering with her DIY Loop insulin pump, drinking strong coffee and reading in front of a cozy fire.